A5013148105- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Pharmaceutical studies and practices
- Pharmacogenetics and Drug Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Psoriasis: Treatment and Pathogenesis
- Genetic Associations and Epidemiology
- Prenatal Screening and Diagnostics
- Schizophrenia research and treatment
- Nutrition, Genetics, and Disease
- Folate and B Vitamins Research
- Dermatology and Skin Diseases
- Pharmaceutical Practices and Patient Outcomes
- Genomic variations and chromosomal abnormalities
- Congenital heart defects research
- Asthma and respiratory diseases
- AI in cancer detection
- Artificial Intelligence in Healthcare and Education
- Lung Cancer Diagnosis and Treatment
- Genomics and Rare Diseases
- Infant Development and Preterm Care
- Lipid metabolism and disorders
- Global Maternal and Child Health
- Innovation Policy and R&D
- Family and Patient Care in Intensive Care Units
Newcastle University
2023-2025
University of Leeds
2016-2023
Leeds Teaching Hospitals NHS Trust
2019-2023
NIHR Leeds In Vitro Diagnostics Co-operative
2018-2021
National Institute for Health Research
2020-2021
PHG Foundation
2010-2016
Genomics (United Kingdom)
2012-2013
Wellcome Sanger Institute
2010
University of Cambridge
2008-2009
MRC Biostatistics Unit
2008-2009
Gurdeep S. Sagoo and colleagues describe key components of the methodology for undertaking systematic reviews meta-analyses genetic association studies.
Over the last decade genomics and other molecular biosciences have enabled new capabilities that, according to many, potential revolutionize medicine healthcare. These developments been associated with a range of terminologies, including 'precision', 'personalized', 'individualized' 'stratified' medicine. In this article, based on literature review, we examine how terms arisen their various meanings definitions. We discuss impact technologies disease classification, prevention management....
<h3>Background</h3> Over recent years genetic testing for germline mutations in <i>BRCA1/BRCA2</i> has become more readily available because of technological advances and reducing costs. <h3>Objective</h3> To explore the feasibility acceptability offering to all women recently diagnosed with epithelial ovarian cancer (EOC). <h3>Methods</h3> Between 1 July 2013 30 June 2015 newly EOC were recruited through six sites East Anglia, UK into Genetic Testing Epithelial Ovarian Cancer (GTEOC) study....
The UK NHS Women's National Breast Screening programme aims to detect breast cancer early. reference standard approach requires mammograms be independently double-read by qualified radiology staff. If two readers disagree, arbitration an independent reader is undertaken. Whilst this process maximises accuracy and minimises recall rates, the procedure labour-intensive, adding pressure a system currently facing workforce crisis. Artificial intelligence technology offers alternative human...
Background and objective As the healthcare industry evolves towards precision medicine, methods to assess value of integrating companion diagnostics in clinical practice through adequate reimbursement levels are becoming essential. Cost-effectiveness analysis is an established tool used inform health technologies. Methods A decision-tree model was developed estimate incremental cost-effectiveness BRCA testing olaparib use versus no standard care (SoC) for patients with BRCA-mutated high-risk...
Abstract Background Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)), showed a survival advantage over standard chemotherapy. Subsequently anti-programmed cell death protein 1 (PD-1) antibodies, nivolumab pembrolizumab were shown to be more effective than ipilimumab. Ipilimumab combined gives an incremental gain in overall...
Geoffrey Rose, in his article “Sick individuals and sick populations” highlighted the need to distinguish between prevention for populations high risk individuals. In this we revisit some of these concepts light burgeoning literature on “personalised medicine” findings from our investigations into personalised cancer as part an EU research gene-environment study hormone related cancers, Collaborative Oncological Gene- environment Study (COGS). We suggest that Rose’s strategy may be modified...
Diagnostic tests are expensive and time-consuming to develop. Early economic evaluation using decision modeling can reduce commercial risk by providing early evidence on cost-effectiveness. The National Institute for Health Research Evidence Co-operatives (DECs) was established catalyze generation diagnostic collaborating with developers; DEC researchers have consequently made extensive use of modeling. aim this article is summarize the experiences DECs diagnostics. We draw 8 case studies...
Evidence is sparse about the genetic determinants of major lipids in Pakistanis.Variants (n=45 000) across 2000 genes were assessed 3200 Pakistanis and compared with 2450 Germans using same gene array similar lipid assays. We also did a meta-analysis selected lipid-related variants Europeans. Pakistani architecture was distinct from that several ethnic groups represented international reference samples. Forty-one at 14 loci significantly associated levels HDL-C, triglyceride, or LDL-C. The...
Introduction In a small percentage of patients, pulmonary nodules found on CT scans are early lung cancers. Lung cancer detected at an stage has much better prognosis. The British Thoracic Society guideline managing recommends using multivariable malignancy risk prediction models to assist in management. While these guidelines seem be effective clinical practice, recent data suggest that artificial intelligence (AI)-based malignant-nodule solutions might outperform existing models. Methods...